Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost

Innovative Medical

Status and phase: Completed; Phase 4

Conditions: Glaucoma

Treatments: Drug: Bimatoprost 0.03%, Latanoprost

Study type: Interventional

Funder types: Industry

Identifiers

NCT00347841

5178

Details and patient eligibility

About

To evaluate the IOP-lowering efficacy of bimatoprost 0.03% in patients found to be low-responders to latanoprost therapy.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• · Male or female > 18 years of age

  • Documented low-responder to latanoprost therapy as delineated in the outline above.
  • Diagnosis of open-angle glaucoma or ocular hypertension
  • Ability to provide informed consent and likely to complete all study visits

Exclusion criteria

• · Known contraindication to bimatoprost or any component of any study medication

  • Uncontrolled systemic disease
  • Active ocular disease other than glaucoma or ocular hypertension
  • Required use of ocular medications other than the study medications during the study (intermittent use of artificial tear solutions will be permitted)
  • History of intraocular surgery within the last 3 months